Journal
ONCOIMMUNOLOGY
Volume 3, Issue 3, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.28245
Keywords
cancer; immunotherapy; anti-OX40; anti-CTLA-4; ipilimumab; interleukin-4; lymphocyte; SPAS-1; prostate cancer; TRAMP-C1
Categories
Ask authors/readers for more resources
It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition to combination therapy significantly improved anti-tumor efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
